Reimagining Indian pharma
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
pharma
April 2021
March 2021
January 2021
April 2020
January 2020
October 2019
July 2019
May 2019
September 2018
August 2018
This decade will mirror the ’90s: Kenneth Andrade
The veteran of the investment industry argues that this decade will witness an export-led growth. And while IT and pharma would rule the economy, other smaller industries, too, will jostle to rise up.
How safe is the Covid-19 vaccine?
As we look ahead to immunisation in 2021, there is the fear of adverse reactions to the drugs as the vaccines have been tested for less than six months. But a framework exists to deal with such cases.
India can reprioritise its global commitments
In a post-coronavirus world, India can become a major provider of global public-goods and services like healthcare.
Learnings from the Indian pharma industry
The difference between industry-leading firms and the rest is the unrelenting focus of the leading ones on brand creation, production and supply chain processes, and product innovation.
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Dr Google, second opinions, and the informed patient
The impact of today’s information-centric culture on healthcare is far-reaching.
Can assistants and surrogates supplement overworked physicians?
A cohort of physician assistants or associates could be of tremendous value in supporting doctors and addressing healthcare gaps in this time of dramatic physician shortages and burnout.
India-U.S. are natural synergistic partners: Kiran MazumdarShaw
Biocon CMD Kiran Mazumdar Shaw speaks to Fortune India on the sidelines of the USIBC India Ideas Summit; says U.S. and India are natural synergistic partners.
‘New complex generics to augur well for Lupin’
Vinita Gupta is confident that new complex generics, specialty drugs and manufacturing quality enhancement plan will augur well for the company
